ijms-logo

Journal Browser

Journal Browser

State-of-the-Art Molecular Oncology in Poland

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Oncology".

Deadline for manuscript submissions: closed (30 April 2023) | Viewed by 4858

Special Issue Editor

Special Issue Information

Dear Colleagues,

Although “cancer” is a very general term for a large number of diseases, there are some common molecular features of tumor cells and their immediate environment that should be studied to improve our understanding of the mechanisms of carcinogenesis. New techniques, including single cell sequencing, liquid biopsy and multiplexing imaging of tumor tissue provide unprecedented opportunities to study cancer in all its complexity. This extended knowledge should create the basis for new diagnostic and therapeutic approaches.

This Special Issue aims to highlight recent advances in cancer research in Poland, focusing on the molecular aspects of carcinogenesis and the new diagnostic/treatment approaches, based on molecular studies.

To provide a comprehensive view of recent advances in cancer research in Poland, we invite researchers to submit original research papers and high-quality comprehensive reviews in the cancer research field to this Special Issue. Potential topics include, but are not limited to, the following:

  • Molecular Aspects of Carcinogenesis;
  • Signaling pathways in cancer;
  • Cell death evasion mechanisms in cancer;
  • Single cell profiling in cancer;
  • The role of microenvironment and immune system.
  • Molecular Oncology in Cancer Diagnostics and Therapy
  • Liquid biopsy; current advances and clinical approaches;
  • New drugs/drug candidates - molecular mechanisms of functioning.

Dr. Ewa A. Grzybowska
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • carcinogenesis
  • metastasis
  • circulating tumor cells
  • tumor microenvironment
  • exosomes
  • immune evasion
  • cell death evasion
  • liquid biopsy
  • tumor heterogeneity
  • single cell profiling

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review

17 pages, 1391 KiB  
Article
Clinical Characterization of Targetable Mutations (BRAF V600E and KRAS G12C) in Advanced Colorectal Cancer—A Nation-Wide Study
by Paweł M. Potocki, Piotr Wójcik, Łukasz Chmura, Bartłomiej Goc, Marcin Fedewicz, Zofia Bielańska, Jakub Swadźba, Kamil Konopka, Łukasz Kwinta and Piotr J. Wysocki
Int. J. Mol. Sci. 2023, 24(10), 9073; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms24109073 - 22 May 2023
Cited by 2 | Viewed by 2111
Abstract
BRAF V600E and KRAS mutations that occur in colorectal cancer (CRC) define a subpopulation of patients with an inferior prognosis. Recently, the first BRAF V600E-targeting therapy has been approved and novel agents targeting KRAS G12C are being evaluated in CRC. A better understanding [...] Read more.
BRAF V600E and KRAS mutations that occur in colorectal cancer (CRC) define a subpopulation of patients with an inferior prognosis. Recently, the first BRAF V600E-targeting therapy has been approved and novel agents targeting KRAS G12C are being evaluated in CRC. A better understanding of the clinical characteristics of the populations defined by those mutations is needed. We created a retrospective database that collects clinical characteristics of patients with metastatic CRC evaluated for RAS and BRAF mutations in a single laboratory. A total of 7604 patients tested between October 2017 and December 2019 were included in the analysis. The prevalence of BRAF V600E was 6.77%. Female sex, primary in the right colon, high-grade, mucinous, signet cell, partially neuroendocrine histology, perineural and vascular invasion, and surgical tissue sample were factors associated with increased mutation rates. The prevalence of KRAS G12C was 3.11%. Cancer of primary origin in the left colon and in samples from brain metastases were associated with increased mutation rates. The high prevalence of the BRAF V600E mutation in cancers with a neuroendocrine component identifies a potential candidate population for BRAF inhibition. The association of KRAS G12C with the left part of the intestine and brain metastases of CRC are new findings and require further investigation. Full article
(This article belongs to the Special Issue State-of-the-Art Molecular Oncology in Poland)
Show Figures

Figure 1

Review

Jump to: Research

29 pages, 1608 KiB  
Review
The Wheel of p53 Helps to Drive the Immune System
by Barbara Łasut-Szyszka and Marek Rusin
Int. J. Mol. Sci. 2023, 24(8), 7645; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms24087645 - 21 Apr 2023
Cited by 7 | Viewed by 2339
Abstract
The p53 tumor suppressor protein is best known as an inhibitor of the cell cycle and an inducer of apoptosis. Unexpectedly, these functions of p53 are not required for its tumor suppressive activity in animal models. High-throughput transcriptomic investigations as well as individual [...] Read more.
The p53 tumor suppressor protein is best known as an inhibitor of the cell cycle and an inducer of apoptosis. Unexpectedly, these functions of p53 are not required for its tumor suppressive activity in animal models. High-throughput transcriptomic investigations as well as individual studies have demonstrated that p53 stimulates expression of many genes involved in immunity. Probably to interfere with its immunostimulatory role, many viruses code for proteins that inactivate p53. Judging by the activities of immunity-related p53-regulated genes it can be concluded that p53 is involved in detection of danger signals, inflammasome formation and activation, antigen presentation, activation of natural killer cells and other effectors of immunity, stimulation of interferon production, direct inhibition of virus replication, secretion of extracellular signaling molecules, production of antibacterial proteins, negative feedback loops in immunity-related signaling pathways, and immunologic tolerance. Many of these p53 functions have barely been studied and require further, more detailed investigations. Some of them appear to be cell-type specific. The results of transcriptomic studies have generated many new hypotheses on the mechanisms utilized by p53 to impact on the immune system. In the future, these mechanisms may be harnessed to fight cancer and infectious diseases. Full article
(This article belongs to the Special Issue State-of-the-Art Molecular Oncology in Poland)
Show Figures

Figure 1

Back to TopTop